Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 1666 of 5804
-
Precision radiation aims to tame scattered tumors
Disease control OngoingThis is a study measuring toxicity while making observations about the survival benefits of treating participants with oligometastatic disease using stereotactic ablative radiotherapy (SABR).
Phase: NA • Sponsor: British Columbia Cancer Agency • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
New drug combo shows promise for tough esophageal cancer
Disease control OngoingThe purpose of this study is to test the safety of adding a new drug, durvalumab (also called MEDI4736), to chemoradiation with either FOLFOX/Capeox or carboplatin and paclitaxel, following initial chemotherapy with FOLFOX. The investigators want to find out what effects, good an…
Phase: PHASE1, PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 26, 2026 13:41 UTC
-
New drug combo shows promise for Drug-Resistant lung cancer
Disease control CompletedThis is a phase Ib, multi-center, open label study evaluating the safety and efficacy of CT053PTSA in combination with gefitinib in patients with EGFR mutation, T790M negative NSCLC who have progressed after EGFR TKI treatment.
Phase: PHASE1, PHASE2 • Sponsor: Sunshine Lake Pharma Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Targeted drug shows promise for rare cancers with cKIT mutation
Disease control OngoingThis phase II MATCH treatment trial tests how well sunitinib in treating patients with cancer that has certain genetic changes. Sunitinib is in a class of medications called kinase inhibitors. It is used in patients whose cancer has a certain mutation (change) in the cKIT gene. I…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Could a new pill help kids fight hepatitis b?
Disease control OngoingThe goals of this clinical study are to compare the effectiveness, safety and tolerability of study drug, tenofovir alafenamide (TAF), versus placebo in teens and children with CHB and to learn more about the dosing levels in children.
Phase: PHASE2 • Sponsor: Gilead Sciences • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Heart risks from breast cancer radiation under the microscope in landmark study
Knowledge-focused Recruiting nowIn Europe, breast cancer is by far the most common form of cancer diagnosed in women today, accounting for 29% of all cases. The 5-year survival rate is approximately 90%. Surgery is usually combined with radiotherapy (RT), anthracyclines, aromatase inhibitors and/or trastuzumab …
Sponsor: St. Olavs Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:02 UTC
-
Could a PARP inhibitor boost chemo for pancreatic cancer?
Disease control CompletedThis randomized phase II trial studies how well modified irinotecan hydrochloride, leucovorin calcium, fluorouracil (FOLFIRI) and veliparib as a second line of therapy work compared to FOLFIRI in treating patients with pancreatic cancer that has come back after a period of improv…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Promising drug cocktail targets tough sarcomas in young patients
Disease control CompletedThe purpose of this study is to see if nab-paclitaxel combined with gemcitabine prevents the formation or growth of tumors in participants with relapsed or refractory osteosarcoma, Ewing sarcoma, rhabdomyosarcoma and other soft tissue sarcoma and to measure the length of time dur…
Phase: PHASE2 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Can switching hormone drugs stall breast cancer when first treatment fails?
Disease control OngoingThis study is being done to look at the role of continuing palbociclib treatment in combination with another type of hormonal therapy (fulvestrant) after disease progression of palbociclib in combination with an aromatase inhibitor.
Phase: PHASE2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
Five-Dose radiation for prostate cancer: does it work and how do patients feel?
Disease control OngoingThe purpose of this study is to learn the long term efficacy and side effects associated with utilizing Stereotactic Body Radiation Therapy (SBRT) radiation for prostate cancer utilizing the Elekta Versa or Agility System. SBRT uses advanced imaging techniques to deliver targeted…
Phase: NA • Sponsor: Hoag Memorial Hospital Presbyterian • Aim: Disease control
Last updated Jun 26, 2026 17:04 UTC
-
Can a pill reach brain tumors? new trial tests ribociclib before surgery
Disease control OngoingIn the proposed trial, patients will be administered ribociclib prior to surgical resection of their tumor. Patients will be enrolled in time-intervals sequentially (non-randomized). All patients will be orally-administered 5 doses of LEE011 (900 mg/d) with the final dose occurri…
Phase: EARLY_PHASE1 • Sponsor: Nader Sanai • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New radiation technique aims to cut side effects in prostate cancer treatment
Disease control OngoingBrachytherapy as a monotherapy treatment is highly effective for localized prostate cancer, traditionally being delivered to the whole prostate gland. Lately, low dose rate (LDR) brachytherapy has been increasingly replaced by high dose rate (HDR) brachytherapy treatment schemes.…
Phase: NA • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New gel wipes out infections after heart surgery in early trial
Prevention CompletedThis study is aimed to assess the anti-infective efficacy of D-PLEX over a period of 3 months post operation as well as the safety over a period of 6 months, by preventing sternal infection post cardiac surgery in patients above the age of 18, including high risk patients for inf…
Phase: PHASE1, PHASE2 • Sponsor: PolyPid Ltd. • Aim: Prevention
Last updated Jun 27, 2026 12:06 UTC
-
New hope for recurrent brain cancer? early trial targets immune suppression
Disease control CompletedThis study involves participants with recurrent glioblastoma brain tumors (GBM). This means that a participant's brain tumor has either returned after being treated by a previous therapy, or has continued to progress despite being treated. The purpose of this study is to provide…
Phase: PHASE1 • Sponsor: Case Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Nightly oxygen may ease sickle cell crisis in pregnancy
Disease control CompletedThe purpose of this study is to assess the efficiency of the preventive oxygen therapy on the occurrence of vaso-occlusive complications, which last more than 24 hours and require hospitalisation, in women with sickle cell disease.
Phase: PHASE3 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
Proton beam vs. standard radiation: which is gentler on head and neck cancer patients?
Symptom relief OngoingCompared to IMRT, PBRT is thought to give less radiation exposure to the surrounding healthy tissues. It is possible that side effect rates with PBRT will be lower or the same compared to IMRT, but this has not been well studied to date. Although both of these radiation therapies…
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 07:56 UTC
-
Can a standardized Watch-and-Wait plan reduce prostate cancer overtreatment?
Disease control OngoingA large proportion of men with prostate cancer are overdiagnosed and overtreated mainly due to PSA testing. Active surveillance (AS) aims to reduce these harms by recommending curative treatment only when and if signs of tumor progression occur. There are however a number of unce…
Phase: NA • Sponsor: Uppsala University • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
New MRI scans could unlock ALS mysteries and speed up drug discovery
Knowledge-focused OngoingRoutine MRI is normal in motor neuron diseases such as ALS. However, advanced MRI techniques can provide an objective measure of degeneration (a "biomarker") by examining brain structure, wiring, chemistry, and function. We will develop and evaluate novel MRI techniques that coul…
Sponsor: University of Alberta • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:30 UTC
-
New brain & blood test combo may spot deadly pregnancy complication earlier
Diagnosis Recruiting nowPre-eclampsia, more than being proteinuric gestational hypertension alone, is a state of exaggerated systemic inflammation and remains a leading direct cause of maternal morbidity and mortality worldwide.1 Standardization of antenatal and postnatal assessment and surveillance of …
Sponsor: Suez Canal University • Aim: Diagnosis
Last updated Jun 27, 2026 12:23 UTC
-
Engineered T-Cells take aim at bladder, skin, and head and neck cancers
Disease control CompletedThis Phase 1 study is designed as a cell dose escalation trial in HLA-A\*02:01 and HLA-A\*02:06 subjects with MAGE-A10 positive urothelial, melanoma or head and neck tumors. The study will enroll subjects between the ages of 18 and 75 using a modified 3+3 cell dose escalation des…
Phase: PHASE1 • Sponsor: Adaptimmune • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC